Authorized purpose: Contour ProtegeAI is used by trained medical professionals as a tool for automated processing of CT and MR medical images. It creates contours with machine-learning algorithms for quantitative analysis, adaptive therapy support, transfer to radiation-treatment planning systems, and archiving, segments normal structures across CT anatomical locations, and segments the prostate, seminal vesicles, and urethra in T2-weighted MR images. It must be used with MIM software to review and, if necessary, edit automatically generated contours.
Clinical role
Radiotherapy contouring, treatment planning, treatment management, image processing, or session support under qualified review and approval.
Images and patients
Radiotherapy Planning Imaging · Normal structures in CT anatomy; prostate, seminal vesicles, and urethra on T2-weighted MR
Key limitation
Keep in mind: Automatically generated contours require review and editing in MIM software; the exact indication does not establish lesion detection or autonomous treatment approval.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Contour ProtegeAI is used by trained medical professionals as a tool for automated processing of CT and MR medical images. It creates contours with machine-learning algorithms for quantitative analysis, adaptive therapy support, transfer to radiation-treatment planning systems, and archiving, segments normal structures across CT anatomical locations, and segments the prostate, seminal vesicles, and urethra in T2-weighted MR images. It must be used with MIM software to review and, if necessary, edit automatically generated contours.
Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Normal structures in CT anatomy; prostate, seminal vesicles, and urethra on T2-weighted MR Input: Supported CT or MR images, structures, prescriptions, treatment plans, registrations, and treatment-session data.
Who uses it?Intended users: Radiation oncologists, medical physicists, dosimetrists, therapists, and other qualified radiation professionals.
What does the software produce?Output: Contours, plans, adapted plans, image-processing results, treatment-management records, or session information requiring professional review.
What is its most important limitation?Key limitation: Automatically generated contours require review and editing in MIM software; the exact indication does not establish lesion detection or autonomous treatment approval.
Clinical takeaway. Clinical role: Contour ProtegeAI is used by trained medical professionals as a tool for automated processing of CT and MR medical images. It creates contours with machine-learning algorithms for quantitative analysis, adaptive therapy support, transfer to radiation-treatment planning systems, and archiving, segments normal structures across CT anatomical locations, and segments the prostate, seminal vesicles, and urethra in T2-weighted MR images. It must be used with MIM software to review and, if necessary, edit automatically generated contours.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports segmentation testing on 286 CT images and 72 MR images from institutions disjoint from the training data, with Contour ProtégéAI and the MIM predicate device both segmenting the test sets. A non-inferiority test of mean Dice coefficient against the predicate showed non-inferiority for all neural network models at a limit of 0.1 Dice. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Contour ProtegeAI is used by trained medical professionals as a tool for automated processing of CT and MR medical images. It creates contours with machine-learning algorithms for quantitative analysis, adaptive therapy support, transfer to radiation-treatment planning systems, and archiving, segments normal structures across CT anatomical locations, and segments the prostate, seminal vesicles, and urethra in T2-weighted MR images. It must be used with MIM software to review and, if necessary, edit automatically generated contours.
Automatically generated contours require review and editing in MIM software; the exact indication does not establish lesion detection or autonomous treatment approval.
The exact FDA document reports segmentation testing on 286 CT images and 72 MR images from institutions disjoint from the training data, with Contour ProtégéAI and the MIM predicate device both segmenting the test sets. A non-inferiority test of mean Dice coefficient against the predicate showed non-inferiority for all neural network models at a limit of 0.1 Dice. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "For testing, 286 images were used to evaluate the neural network models that segmented CT images, while 72 images were used to evaluate for the MR segmentation network." … "In all cases, the test images were gathered from a different and disjoint set of institutions from the training data.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports segmentation testing on 286 CT images and 72 MR images from institutions disjoint from the training data, with Contour ProtégéAI and the MIM predicate device both segmenting the test sets. A non-inferiority test of mean Dice coefficient against the predicate showed non-inferiority for all neural network models at a limit of 0.1 Dice. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "For testing, 286 images were used to evaluate the neural network models that segmented CT images, while 72 images were used to evaluate for the MR segmentation network." … "In all cases, the test images were gathered from a different and disjoint set of institutions from the training data.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K193252 FDA decision evidence package for Contour ProtegeAI
DesignFDA decision evidence and product verification described in the exact submission or PMA decision record.
PopulationNormal structures in CT anatomy; prostate, seminal vesicles, and urethra on T2-weighted MR
Scopeexact submission
Tested versionContour ProtegeAI configuration described in K193252
IndependenceSponsor or vendor study
K193252
FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation unless the exact source expressly establishes that distinction; local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K193252 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported CT or MR images, structures, prescriptions, treatment plans, registrations, and treatment-session data.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes Contour ProtégéAI processing CT and MR images as supported by ACR/NEMA DICOM 3.0, using the MIMcloud service for data management and transfer, and creating contours for applications including transfer to radiation therapy treatment planning systems and archiving. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "Contour ProtégéAI is used by trained medical professionals as a tool to aid in the automated processing of digital medical images of modalities CT and MR, as supported by ACR/NEMA DICOM 3.0." … "The creation of contours using machine-learning algorithms for applications including, but not limited to, quantitative analysis, aiding adaptive therapy, transferring contours to radiation therapy treatment planning systems, and archiving contours for patient follow-up". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Contour ProtégéAI as deployed on a remote server using the MIMcloud service for data management and transfer, and as operating on Windows, Mac, and Linux computer systems. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "It is designed for use in the processing of medical images and operates on Windows, Mac, and Linux computer systems." … "Contour ProtégéAI is deployed on a remote server using the MIMcloud service for data management and transfer.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Contours, plans, adapted plans, image-processing results, treatment-management records, or session information requiring professional review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Contours, plans, adapted plans, image-processing results, treatment-management records, or session information requiring professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Contour ProtégéAI as deployed on a remote server using the MIMcloud service for data management and transfer, and as operating on Windows, Mac, and Linux computer systems. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "It is designed for use in the processing of medical images and operates on Windows, Mac, and Linux computer systems." … "Contour ProtégéAI is deployed on a remote server using the MIMcloud service for data management and transfer.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes Contour ProtégéAI processing CT and MR images as supported by ACR/NEMA DICOM 3.0, using the MIMcloud service for data management and transfer, and creating contours for applications including transfer to radiation therapy treatment planning systems and archiving. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Contour ProtégéAI is used by trained medical professionals as a tool to aid in the automated processing of digital medical images of modalities CT and MR, as supported by ACR/NEMA DICOM 3.0." … "The creation of contours using machine-learning algorithms for applications including, but not limited to, quantitative analysis, aiding adaptive therapy, transferring contours to radiation therapy treatment planning systems, and archiving contours for patient follow-up". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
MIM Software's security page states SOC 2 Type 2 status, penetration testing and continuous vulnerability scanning of released products, coordinated vulnerability disclosure and a public security advisories page. Vendor-wide.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
Only radiation oncologists, medical physicists, dosimetrists, therapists, and other qualified radiation professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K193252 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Automatically generated contours require review and editing in MIM software; the exact indication does not establish lesion detection or autonomous treatment approval.
Exact FDA submission
Checked 2026-09-04
This is buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.
The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.
exact submission · checked 2026-09-04
FDA-described topology does not establish current hosting contracts, security controls, uptime, or local qualification.
The exact public integration contract remains incomplete; establish and test supported input, output, identity, routing, archive, and downtime behavior locally.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Automatically generated contours require review and editing in MIM software; the exact indication does not establish lesion detection or autonomous treatment approval.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
exact submission · checked 2026-09-04
No exact-product price or reimbursement determination was promoted.
Monitor K193252 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Automatically generated contours require review and editing in MIM software; the exact indication does not establish lesion detection or autonomous treatment approval.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, vendor documentation, fda decision material, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission
No exact-product reimbursement determination was promoted in this timeboxed review. Verify payer, site-of-service, coding, coverage, and local payment assumptions independently.
Authorized purpose: Contour ProtégéAI+ automatically creates contours on CT and T2 MR DICOM images as an accessory to MIM software for quantitative analysis, adaptive therapy, transfer, and archive; users must review and edit contours, and the device is not intended to detect or contour lesions.
Modality
Radiotherapy Planning Imaging
Anatomy
CT anatomical regions; prostate, seminal vesicles, and urethra on T2 MR
Authorized purpose: Contour ProtegeAI assists trained medical professionals with automated processing of CT and MR images, creates machine-learning contours for quantitative analysis, adaptive therapy, transfer to radiation-treatment planning systems, and archiving, segments structures across CT locations, and segments the prostate, seminal vesicles, and urethra on T2-weighted MR images.
Modality
Radiotherapy Planning Imaging
Anatomy
CT anatomic locations and the prostate, seminal vesicles, and urethra on T2-weighted MR
Authorized purpose: Contour ProtegeAI assists trained medical professionals with automated processing of CT and MR images, machine-learning contour creation for quantitative analysis, adaptive therapy, transfer to radiation-treatment planning systems, and archiving, segmentation across CT locations, and segmentation of the prostate, seminal vesicles, and urethra on T2-weighted MR images.
Modality
Radiotherapy Planning Imaging
Anatomy
CT anatomic locations and the prostate, seminal vesicles, and urethra on T2-weighted MR
Authorized purpose: Contour ProtégéAI creates machine-learning contours from CT and MR DICOM images to support quantitative analysis, adaptive therapy, radiotherapy planning, archiving, and follow-up; professionals must visualize, review, and edit contours, and the software is not intended to detect or contour lesions.
Modality
Radiotherapy Planning Imaging
Anatomy
Normal structures in labeled CT locations; prostate, seminal vesicles, and urethra on T2 MR
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.